Clinical Trials Search | Clareo Health

Showing 1-2 of 2 trials

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT06462469

The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).

Steroid-refractory Acute Graft Versus Host Disease

Novartis Pharmaceuticals36 participantsStarted Jul 2024

Guangzhou, Guangdong, China • Guangzhou, Guangdong, China • Zhengzhou, Henan, China +14 more locations

TERMINATEDPhase 3

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319

The study is designed as an open-label, single arm Phase III, multicenter trial to evaluate the efficacy and safety of T-Guard treatment in patients with Steroid-Refractory acute Graft versus Host Disease (SR-aGVHD).

Steroid-Refractory Acute Graft Versus Host Disease

Xenikos3 participantsStarted Nov 2019

Duarte, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +21 more locations

Data from ClinicalTrials.govTerms

Showing 1-2 of 2 trials

RECRUITINGPhase 4

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

NCT06462469

The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).

Steroid-refractory Acute Graft Versus Host Disease

Novartis Pharmaceuticals36 participantsStarted Jul 2024

Guangzhou, Guangdong, China • Guangzhou, Guangdong, China • Zhengzhou, Henan, China +14 more locations

TERMINATEDPhase 3

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

NCT04128319

The study is designed as an open-label, single arm Phase III, multicenter trial to evaluate the efficacy and safety of T-Guard treatment in patients with Steroid-Refractory acute Graft versus Host Disease (SR-aGVHD).

Steroid-Refractory Acute Graft Versus Host Disease

Xenikos3 participantsStarted Nov 2019

Duarte, California, United States • Los Angeles, California, United States • Washington D.C., District of Columbia, United States +21 more locations

Data from ClinicalTrials.govTerms

Filters

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)

Study of Efficacy and Safety of Ruxolitinib in Patients With Grade II to IV Steroid-refractory Acute Graft vs. Host Disease

T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)